$-0.04 EPS Expected for Iteris, Inc. (ITI); Baker Bros Advisors LP Has Cut Sangamo Therapeutics (SGMO) Holding By $30.00 Million

January 16, 2018 - By Linda Rogers

Analysts expect Iteris, Inc. (NASDAQ:ITI) to report $-0.04 EPS on February, 8.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.04 EPS. After having $-0.03 EPS previously, Iteris, Inc.’s analysts see 33.33% EPS growth. The stock decreased 0.73% or $0.06 during the last trading session, reaching $7.47. About 364,257 shares traded or 77.27% up from the average. Iteris, Inc. (NASDAQ:ITI) has risen 136.03% since January 16, 2017 and is uptrending. It has outperformed by 119.33% the S&P500.

Baker Bros Advisors Lp decreased Sangamo Therapeutics Inc. (SGMO) stake by 48.62% reported in 2017Q3 SEC filing. Baker Bros Advisors Lp sold 2.00M shares as Sangamo Therapeutics Inc. (SGMO)’s stock rose 95.00%. The Baker Bros Advisors Lp holds 2.11M shares with $31.70 million value, down from 4.11M last quarter. Sangamo Therapeutics Inc. now has $1.55 billion valuation. The stock increased 6.71% or $1.15 during the last trading session, reaching $18.3. About 2.27 million shares traded or 61.87% up from the average. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since January 16, 2017 and is uptrending. It has outperformed by 13.08% the S&P500.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences had 22 analyst reports since August 8, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of SGMO in report on Friday, September 4 with “Buy” rating. The company was maintained on Wednesday, September 2 by Wedbush. On Thursday, August 10 the stock rating was maintained by Piper Jaffray with “Hold”. As per Thursday, August 4, the company rating was downgraded by Janney Capital. Jefferies maintained it with “Buy” rating and $18.0 target in Tuesday, September 12 report. The stock has “Hold” rating by Wedbush on Monday, August 14. The company was downgraded on Tuesday, November 1 by Wedbush. As per Thursday, June 22, the company rating was reinitiated by Jefferies. As per Wednesday, November 15, the company rating was upgraded by PiperJaffray. Wedbush maintained it with “Hold” rating and $6.0 target in Wednesday, November 15 report.

Since August 11, 2017, it had 0 insider purchases, and 6 sales for $1.36 million activity. 11,474 shares valued at $119,740 were sold by Herberts Curt A. III on Friday, August 11. 31,000 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares with value of $445,597 were sold by RINGO WILLIAM R. Conner Edward R. sold $85,545 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Monday, January 8.

Investors sentiment decreased to 1.57 in Q3 2017. Its down 0.02, from 1.59 in 2017Q2. It is negative, as 17 investors sold SGMO shares while 32 reduced holdings. 27 funds opened positions while 50 raised stakes. 51.93 million shares or 2.16% more from 50.83 million shares in 2017Q2 were reported. Alliancebernstein LP reported 0% stake. Weiss Multi invested in 0.03% or 50,000 shares. Prelude Capital Mgmt Limited Liability Corporation owns 1,350 shares or 0% of their US portfolio. Wasatch Advsr holds 5.19 million shares or 1.06% of its portfolio. Thompson Davis And holds 1,500 shares or 0.04% of its portfolio. Advisory Ser Net Limited Com holds 300 shares. 12,800 are owned by Ellington Mgmt Grp Inc Ltd Liability Corporation. State Bank Of America De holds 0% or 26,872 shares in its portfolio. State Street owns 2.89M shares for 0% of their portfolio. Ubs Asset Management Americas invested in 0% or 21,498 shares. Fmr Ltd Company reported 2.84M shares. Keybank Natl Association Oh reported 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Bnp Paribas Arbitrage Sa, New York-based fund reported 8,140 shares. Royal Commercial Bank Of Canada has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). 11,528 were accumulated by Janney Montgomery Scott Lc.

Baker Bros Advisors Lp increased Acceleron Pharma Inc. (NASDAQ:XLRN) stake by 135,135 shares to 163,900 valued at $6.12M in 2017Q3. It also upped Array Biopharma Inc. (NASDAQ:ARRY) stake by 3.63M shares and now owns 5.21 million shares. Ignyta Inc. (NASDAQ:RXDX) was raised too.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.18 EPS, down 28.57% or $0.04 from last year’s $-0.14 per share. After $-0.15 actual EPS reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.